Alice Covizzi

Scopus Publications

Gastritis and AIDS-related cholangiopathy as an unusual presentation of HIV infection
Fabio Brivio, Alice Covizzi, Davide Bernasconi, Guido Gubertini, Monica Schiavini, Silvia Grosso, Luca Carsana, Massimo Tonolini, Manuela Nebuloni, Andrea Gori, Emanuele Palomba
Gastroenterology Report, 2026
Recrudescence of Plasmodium falciparum malaria imported from Sub-Saharan Africa: a report of two cases and the first detection of artemisinin resistance in Italy
Mariangela L’Episcopia, Andrea Poloni, Mario Corbellino, Daniela Boccolini, Anna Gigantiello, Alice Covizzi, Davide Bernasconi, Valeria Colombo, Carlo Severini, Spinello Antinori
Travel Medicine and Infectious Disease, 2026
BACKGROUND: Artemisinin-based combination therapy for Plasmodium falciparum malaria is threatened by the emergence of partial resistance. METHODS: Molecular characterization of antimalarial resistance-associated genes Pfk13, Pfcrt, Pfmdr1, Pfdhfr, Pfdhps and PfCytB was performed on blood samples collected from two patients with recurrent episodes of P. falciparum malaria. RESULTS: Two severe P. falciparum malaria in Italian travelers from sub-Saharan Africa showed recrudescence after standard treatment with intravenous artesunate and oral dihydroartemisinin-piperaquine. In one case, the validated marker R561H of artemisinin partial resistance was identified. In the second patient, no Pfkelch13 mutations were detected, and the recrudescent episode was probably the consequence of low blood drug concentration administered by nasogastric tube, although the possible role of Pfkelch13-independent pathways or reduced artemisinin susceptibility cannot be ruled out. CONCLUSION: The first imported case of artemisinin-resistant P. falciparum in Italy from sub-Saharan Africa underscores the need for continuous surveillance and eventually adapting treatment protocols.
Breaking barriers in extensively drug-resistant TB: pretomanid-centred long regimen achieves cure in a bedaquiline-resistant strain
M. Schiuma, A. Piubello, F. Saluzzo, D. Cattaneo, F. Salari, A. Covizzi, A. Rizzo, F. Fama, C. Ciubotariu, A. Lombardi, S. Antinori, A. Riva, D.M. Cirillo, A. Gori, A. Torre
Ijtld Open, 2026
Proactive Therapeutic Drug MONiToring to Guide Suppressive Antibiotic Therapy with DALBAvaNcin (>12 weeks) in Osteoarticular Infections (MONTALBANO)
Chiara Mariani, Matteo Passerini, Lucia Galli, Alice Covizzi, Marta Colaneri, Martina Offer, Margherita Faenzi, Stefania Merli, Simona Landonio, Marta Fusi, Alberto Dolci, Andrea Gori, Dario Cattaneo
Journal of Bone and Joint Infection, 2025
Introduction: Long-term dalbavancin use is increasingly adopted off-label for osteoarticular infections (OAIs), but data on administration timing and long-term effects beyond 12 weeks are scarce. This study evaluated the pharmacological efficacy of proactive therapeutic drug monitoring (TDM) to optimize dalbavancin administration. Methods: This single-center, retrospective study included adult OAI patients treated with ≥4 doses of dalbavancin from July 2022 to October 2024. Initial doses were given on days 1, 8, and 43. From the third dose onward, Cmin⁡ and Cmax⁡ values informed dosing schedules via log-linear regression models, targeting Cmin⁡≥8 mg L−1. The primary outcome was the pharmacological efficacy of dalbavancin, assessed by the proportion of patients with Cmin⁡≥8 mg L−1 and ≥4 mg L−1 after the third dose. Clinical outcomes and safety data were collected as descriptive data. Results: A total of 33 patients provided 118 Cmin⁡ determinations. Pharmacological efficacy was achieved in 93/118 (78.8 %) and 114/118 (96.6 %) determinations for Cmin⁡ thresholds of ≥8 mg L−1 and ≥4 mg L−1, respectively. Efficacy improved when considering only determinations at the correct timing. A total of 18 (54.5 %) patients are still in treatment, while 11 (33.3 %) completed therapy with clinical success. Three patients experienced a relapse after the end of the treatment, while one patient experienced failure, and no adverse events were reported. Conclusions: Dalbavancin is a viable option for prolonged OAI management when other therapies are unavailable or high-risk. Proactive TDM effectively supports this approach by ensuring adequate drug exposure while preventing accumulation.
NAT2 Acetylation Status Predicts Hepatotoxicity During Antituberculosis Therapy: Cumulative Risk Analysis of a Multiethnic Cohort
Marco Schiuma, Sofia Dinegro, Vera Battini, Alessandro Torre, Alice Covizzi, Aurora Civati, Miriam Galimberti, Ilaria Mariani, Giulia Mosini, Carla Carnovale, Agostino Riva, Andrea Gori, Spinello Antinori, Emilio Clementi, Sonia Radice, Stefania Cheli
International Journal of Molecular Sciences, 2025
Antituberculosis drug-induced hepatotoxicity (ATDH) is a common adverse drug reaction often requiring treatment interruption, complicating tuberculosis management. The slow acetylator phenotype, characterized by reduced N-acetyltransferase 2 (NAT2) enzyme activity, is associated with increased hepatotoxicity risk, while rapid acetylators are associated with a higher risk of therapeutic failure. This study investigates the association between the NAT2 acetylation phenotype and ATDH occurrence, with an emphasis on its predictive value in regard to a multiethnic population and its impact on the timing of ATDH onset. A retrospective observational study was conducted on tuberculosis patients treated at Luigi Sacco Hospital, Milan, Italy (July 2020–September 2023). The NAT2 genotyping identified slow and rapid/intermediate acetylators. Cumulative incidence analysis and Fine–Gray competing risks regression models were used to assess ATDH risk and onset timing. Among 102 patients, 21.6% developed ATDH, including 16.7% with slow and 4.9% with rapid/intermediate acetylators. ATDH onset was significantly earlier in regard to slow acetylators (median 0.5 vs. 2 months, interquartile range-IQR: 0.5–3 vs. 1.7–5.5). Slow acetylators were associated with a higher risk of developing ATDH (Sub-distribution hazard ratio, SHR = 3.05; 95% confidence interval-CI: 1.17–7.95; p = 0.02), even after adjusting for confounders. The NAT2 acetylation phenotype strongly influences ATDH risk and timing. Early acetylator status identification may enable dose adjustments, enhancing treatment safety. These findings highlight the role of pharmacogenetics in optimizing antituberculosis therapy by improving efficacy and minimizing toxicity.
SARS-CoV-2 infectivity can be modulated through bacterial grooming of the glycocalyx
Cameron Martino, Benjamin P. Kellman, Daniel R. Sandoval, Thomas Mandel Clausen, Robert Cooper, Alhosna Benjdia, Feryel Soualmia, Alex E. Clark, Aaron F. Garretson, Clarisse A. Marotz, Se Jin Song, Stephen Wandro, Livia S. Zaramela, Rodolfo A. Salido, Qiyun Zhu, Erick Armingol, Yoshiki Vázquez-Baeza, Daniel McDonald, James T. Sorrentino, Bryn Taylor, Pedro Belda-Ferre, Promi Das, Farhana Ali, Chenguang Liang, Yujie Zhang, Luca Schifanella, Alice Covizzi, Alessia Lai, Agostino Riva, Christopher Basting, Courtney Ann Broedlow, Aki S. Havulinna, Pekka Jousilahti, Mehrbod Estaki, Tomasz Kosciolek, Rayus Kuplicki, Teresa A. Victor, Martin P. Paulus, Kristen E. Savage, Jennifer L. Benbow, Emma S. Spielfogel, Cheryl A. M. Anderson, Maria Elena Martinez, James V. Lacey, Shi Huang, Niina Haiminen, Laxmi Parida, Ho-Cheol Kim, Jack A. Gilbert, Daniel A. Sweeney, Sarah M. Allard, Austin D. Swafford, Susan Cheng, Michael Inouye, Teemu Niiranen, Mohit Jain, Veikko Salomaa, Karsten Zengler, Nichole R. Klatt, Jeff Hasty, Olivier Berteau, Aaron F. Carlin, Jeffrey D. Esko, Nathan E. Lewis, Rob Knight
Mbio, 2025
The gastrointestinal (GI) tract is a site of replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and GI symptoms are often reported by patients. SARS-CoV-2 cell entry depends upon heparan sulfate (HS) proteoglycans, which commensal bacteria that bathe the human mucosa are known to modify. To explore human gut HS-modifying bacterial abundances and how their presence may impact SARS-CoV-2 infection, we developed a task-based analysis of proteoglycan degradation on large-scale shotgun metagenomic data. We observed that gut bacteria with high predicted catabolic capacity for HS differ by age and sex, factors associated with coronavirus disease 2019 (COVID-19) severity, and directly by disease severity during/after infection, but do not vary between subjects with COVID-19 comorbidities or by diet. Gut commensal bacterial HS-modifying enzymes reduce spike protein binding and infection of authentic SARS-CoV-2, suggesting that bacterial grooming of the GI mucosa may impact viral susceptibility. IMPORTANCE Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019, can infect the gastrointestinal (GI) tract, and individuals who exhibit GI symptoms often have more severe disease. The GI tract’s glycocalyx, a component of the mucosa covering the large intestine, plays a key role in viral entry by binding SARS-CoV-2’s spike protein via heparan sulfate (HS). Here, using metabolic task analysis of multiple large microbiome sequencing data sets of the human gut microbiome, we identify a key commensal human intestinal bacteria capable of grooming glycocalyx HS and modulating SARS-CoV-2 infectivity in vitro . Moreover, we engineered the common probiotic Escherichia coli Nissle 1917 (EcN) to effectively block SARS-CoV-2 binding and infection of human cell cultures. Understanding these microbial interactions could lead to better risk assessments and novel therapies targeting viral entry mechanisms.
Corrigendum: Understanding the burden of antibiotic resistance: a decade of carbapenem-resistant Gram-negative bacterial infections in Italian intensive care units (Frontiers in Microbiology, (2024), 15, (1405390), 10.3389/fmicb.2024.1405390)
Giovanni Scaglione, Matilde Perego, Marta Colaneri, Camilla Genovese, Fabio Brivio, Alice Covizzi, Bruno Viaggi, Alessandra Bandera, Andrea Gori, Stefano Finazzi, Emanuele Palomba
Frontiers in Microbiology, 2025
In the published article, there was an error in Figure 6 as published. In Figure 6 the percentage of carbapenem-resistant strains was not correct. The corrected Figure 6 and its caption **Figure 6. Distribution of infections caused by Acinetobacter spp. acquired in intensive care during the study period, overall and for infection site, with the relative prevalence of carbapenem-resistant strains. appear below.The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.Reminder: Figures, tables, and images will be published under a Creative Commons CC-BY licence and permission must be obtained for use of copyrighted material from other sources (including re-published/adapted/modified/partial figures and images from the internet). It is the responsibility of the authors to acquire the licenses, to follow any citation instructions requested by third-party rights holders, and cover any supplementary charges. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.In the published article, there was an error. The percentages of carbapenem-resistant Acinetobacter spp. strains were not correct.A correction has been made to Results, 3.2.3 Acinetobacter spp. infections. This sentence previously stated: "Acinetobacter spp. was the least frequently isolated GNB of the three in study (2183/25966, 8.4%) and displayed the overall lowest rates of resistance to carbapenems (290/2183, 13.3%). This pathogen was mainly responsible for VAP (1146/9260, 12.4%) and to a lesser extent for IAI (171/1921, 9.0%), BSI (147/2940, 5.0%), and UTI (77/1959, 3.9%). The carbapenem resistance proportion was the highest in BSI (19/147, 13.0%), followed by VAP (130/1146, 11.3%), UTI (7/77, 9.1%) and IAI (14/171, 8.2%). Carbapenem-resistant Acinetobacter spp. rates varied greatly from one year to the other and this pathogen was most prevalent in the years 2019 (21%) and 2022 (19.2%)"The corrected sentence appears below: "Acinetobacter spp. was the least frequently isolated GNB of the three in study (2183/25966, 8.4%) and displayed the overall highest rates of resistance to carbapenems (1893/2183, 86.7%). This pathogen was mainly responsible for VAP (1146/9260, 12.4%) and to a lesser extent for IAI (171/1921, 9.0%), BSI (147/2940, 5.0%), and UTI (77/1959, 3.9%). The carbapenem resistance proportion was the highest in IAI (157/171, 91.8%), followed by UTI (70/77, 90.1%), VAP (1016/1146, 88.7%), and BSI (130/147, 88.4%). Carbapenem-resistant Acinetobacter spp. rates varied greatly from one year to the other, with a peak of 91.9% in 2020."A correction has been made to Discussion. This sentence previously stated:"The findings of our study shed light on the epidemiology of HAIs in Italian ICUs over a tenyear period. Our analysis reveals a substantial burden of HAIs, with an average of 1.5 infections per patient over the study period, with high prevalence of CR-GNB, particularly Pseudomonas aeruginosa, Klebsiella and Acinetobacter species. This trend was mainly driven by Klebsiella spp. and Pseudomonas aeruginosa, with 31.4% and 21.8% of isolate showing this susceptibility profile, respectively. In particular, CR-GNB accounted for a third of IAI and a quarter of each VAP, BSI and UTI caused by these pathogens. Finally, during the SARS-CoV-2 pandemic, ICU-PAGE \* Arabic \* MERGEFORMAT 3HAIs showed a peak in both incidence and CR-GNB rates, in contrast to a previously declining trend."The corrected sentence appears below:"The findings of our study shed light on the epidemiology of HAIs in Italian ICUs over a tenyear period. Our analysis reveals a substantial burden of HAIs, with an average of 1.5 infections per patient over the study period, with high prevalence of CR-GNB, particularly Pseudomonas aeruginosa, Klebsiella and Acinetobacter species. This trend was mainly driven by Klebsiella spp. and Pseudomonas aeruginosa, with 31.4% and 21.8% of isolate showing this susceptibility profile, respectively. In particular, CR-GNB accounted for a third of IAI and a quarter of each VAP, BSI and UTI caused by these pathogens. Notably, over the course of the decade, up to 90% of Acinetobacter spp. isolates retrieved showed carbapenem-resistant. Finally, during the SARS-CoV-2 pandemic, ICU-HAIs showed a peak in both incidence and CR-GNB rates, in contrast to a previously declining trend."A correction has been made to Discussion. This sentence previously stated: "In our cohort, Acinetobacter spp. caused less than one tenth of all ICU-acquired infections and showed the overall lowest rates of resistance to carbapenems (13.3%). This data is in contrast with European and national reports, where carbapenem-resistant strains account for up to one third of all isolates globally, with even higher percentages in Italy, where carbapenem-resistance in Acinetobacter baumannii reaches peaks of 88% (European Centre for Disease Prevention and Control, 2022). These differences may be explained by the higher prevalence of carbapenemresistant strains in settings different than ICU, as other European studies have already observed (Said et al., 2021;Kinross et al., 2022). Furthermore, our analysis only included infections diagnosed by a physician and did not consider respiratory, intestinal and device colonisations, which are often characteristic of Acinetobacter species. Finally, we considered all Acinetobacter spp. strains, not focusing only on Acinetobacter baumannii, which may have partially lowered the overall prevalence of carbapenem-resistance. As confirmed by our findings, infections caused by Acinetobacter spp. typically exhibit a varied distribution, marked by sporadic outbreaks, thereby serving as an indicator for evaluating infection control and prevention strategies. The emergence of the SARS-CoV-2 pandemic has accentuated these distinctive patterns, highlighting avenues for enhancing management approaches (Mangioni et al., 2023b)."The corrected sentence appears below: "In our cohort, Acinetobacter spp. caused less than one tenth of all ICU-acquired infections and showed the overall highest rates of resistance to carbapenems (86.7%). This data is in line with European and national reports, where carbapenem-resistant strains account for up to one third of all isolates globally, with even higher percentages in Italy, where carbapenem-resistance in
Understanding the burden of antibiotic resistance: a decade of carbapenem-resistant Gram-negative bacterial infections in Italian intensive care units
Giovanni Scaglione, Matilde Perego, Marta Colaneri, Camilla Genovese, Fabio Brivio, Alice Covizzi, Bruno Viaggi, Alessandra Bandera, Andrea Gori, Stefano Finazzi, Emanuele Palomba
Frontiers in Microbiology, 2024
IntroductionIn patients admitted to intensive care units (ICUs), Gram-negative bacteria (GNB) infections pose significant challenges due to their contribution to morbidity, mortality, and healthcare costs. During the SARS-CoV-2 pandemic, Italy witnessed a rise in healthcare-associated infections (HAIs), with GNBs involved in a substantial proportion of cases. Concerningly, carbapenem-resistant GNBs (CR-GNBs) have increased worldwide, posing therapeutic challenges.MethodsRetrospective multicentre study analysing data from over 299,000 patients admitted to Italian ICUs from 2013 to 2022.ResultsThe study revealed an average of 1.5 infections per patient, with HAIs peaking during the pandemic years. Ventilator associated pneumonia (VAP) emerged as the most common HAI, with Klebsiella spp. and Pseudomonas aeruginosa predominating. Alarmingly, CR-GNBs accounted for a significant proportion of infections, particularly in VAP, bloodstream infections, and intra-abdominal infections.DiscussionOur findings underscore the pressing need for enhanced infection control measures, particularly in the ICU setting, to mitigate the rising prevalence of CR-GNBs and their impact on patient outcomes. The study provides valuable insights into the epidemiology of HAIs in Italian ICUs and highlights the challenges posed by CR-GNBs, especially in the context of the SARS-CoV-2 pandemic, which exacerbated the issue and may serve as a crucial example for the management of future viral pandemics.
Comparative analysis of spike-specific IgG Fc glycoprofiles elicited by adenoviral, mRNA, and protein-based SARS-CoV-2 vaccines
Julie Van Coillie, Tamas Pongracz, Tonći Šuštić, Wenjun Wang, Jan Nouta, Mathieu Le Gars, Sofie Keijzer, Federica Linty, Olvi Cristianawati, Jim B.D. Keijser, Remco Visser, Lonneke A. van Vught, Marleen A. Slim, Niels van Mourik, Merel J. Smit, Adam Sander, David E. Schmidt, Maurice Steenhuis, Theo Rispens, Morten A. Nielsen, Benjamin G. Mordmüller, Alexander P.J. Vlaar, C. Ellen van der Schoot, Ramon Roozendaal, Manfred Wuhrer, Gestur Vidarsson, Brent Appelman, Diederik van de Beek, Marije K. Bomers, Justin de Brabander, Matthijs C. Brouwer, David T.P. Buis, Nora Chekrouni, Marit J. van Gils, Menno D. de Jong, Ayesha H.A. Lavell, Niels van Mourik, Sabine E. Olie, Edgar J.G. Peters, Tom D.Y. Reijnders, Michiel Schinkel, Alex R. Schuurman, Jonne J. Sikkens, Marleen A. Slim, Yvo M. Smulders, Alexander P.J. Vlaar, Lonneke A. van Vught, Joost W. Wiersinga, Antinori Spinello, Cinzia Bassoli, Giovanna Bestetti, Mario Corbellino, Alice Covizzi, Angelica Lupo, Laura Milazzo, Marco Schiuma, Alessandro Torre, Willem A. de Jongh, Ali Salanti, Thor G. Theander, Matthew B.B. McCall, Meral Esen
Iscience, 2023
IgG antibodies are important mediators of vaccine-induced immunity through complement- and Fc receptor-dependent effector functions. Both are influenced by the composition of the conserved N -linked glycan located in the IgG Fc domain. Here, we compared the anti-Spike (S) IgG1 Fc glycosylation profiles in response to mRNA, adenoviral, and protein-based COVID-19 vaccines by mass spectrometry (MS). All vaccines induced a transient increase of antigen-specific IgG1 Fc galactosylation and sialylation. An initial, transient increase of afucosylated IgG was induced by membrane-encoding S protein formulations. A fucose-sensitive ELISA for antigen-specific IgG (FEASI) exploiting FcγRIIIa affinity for afucosylated IgG was used as an orthogonal method to confirm the LC-MS-based afucosylation readout. Our data suggest that vaccine-induced anti-S IgG glycosylation is dynamic, and although variation is seen between different vaccine platforms and individuals, the evolution of glycosylation patterns display marked overlaps.
Immunogenicity of two doses of BNT162b2 and mRNA-1273 vaccines for solid cancer patients on treatment with or without a previous SARS-CoV-2 infection
Nicla La Verde, Agostino Riva, Maria Silvia Cona, Arianna Gabrieli, Monica Cattaneo, Cinzia Fasola, Giuseppe Lipari, Claudia De Stradis, Valentina Favorito, Benedetta Lombardi Stocchetti, Davide Chizzoniti, Alice Covizzi, Eliana Rulli, Francesca Galli, Lorenzo Ruggieri, Anna Gambaro, Sabrina Ferrario, Davide Dalu, Maciej S. Tarkowski
International Journal of Cancer, 2023
Previous studies on the immunogenicity of SARS‐CoV‐2 mRNA vaccines showed a reduced seroconversion in cancer patients. The aim of our study is to evaluate the immunogenicity of two doses of mRNA vaccines in solid cancer patients with or without a previous exposure to the virus. This is a single‐institution, prospective, nonrandomized study. Patients in active treatment and a control cohort of healthy people received two doses of BNT162b2 (Comirnaty, BioNTech/Pfizer, The United States) or mRNA‐1273 (Spikevax, Moderna). Vaccine was administered before starting anticancer therapy or on the first day of the treatment cycle. SARS‐CoV‐2 antibody levels against S1, RBD (to evaluate vaccine response) and N proteins (to evaluate previous infection) were measured in plasma before the first dose and 30 days after the second one. From January to June 2021, 195 consecutive cancer patients and 20 healthy controls were enrolled. Thirty‐one cancer patients had a previous exposure to SARS‐CoV‐2. Cancer patients previously exposed to the virus had significantly higher median levels of anti‐S1 and anti‐RBD IgG, compared to healthy controls (P = .0349) and to cancer patients without a previous infection (P < .001). Vaccine type (anti‐S1: P < .0001; anti‐RBD: P = .0045), comorbidities (anti‐S1: P = .0274; anti‐RBD: P = .0048) and the use of G‐CSF (anti‐S1: P = .0151) negatively affected the antibody response. Conversely, previous exposure to SARS‐CoV‐2 significantly enhanced the response to vaccination (anti‐S1: P < .0001; anti‐RBD: P = .0026). Vaccine immunogenicity in cancer patients with a previous exposure to SARS‐CoV‐2 seems comparable to that of healthy subjects. On the other hand, clinical variables of immune frailty negatively affect humoral immune response to vaccination.
Corrigendum: Definition of the immune parameters related to COVID-19 severity (Frontiers in Immunology, (2023), 14, (1204125), 10.3389/fimmu.2023.1204125)
Sarah Birindelli, Maciej S. Tarkowski, Marcello Gallucci, Marco Schiuma, Alice Covizzi, Przemysław Lewkowicz, Elena Aloisio, Felicia Stefania Falvella, Alberto Dolci, Agostino Riva, Massimo Galli, Mauro Panteghini
Frontiers in Immunology, 2023
The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not in antigen-experienced vaccinees
Julie Van Coillie, Tamas Pongracz, Johann Rahmöller, Hung-Jen Chen, Chiara Elisabeth Geyer, Lonneke A. van Vught, Jana Sophia Buhre, Tonći Šuštić, Thijs Luc Junior van Osch, Maurice Steenhuis, Willianne Hoepel, Wenjun Wang, Anne Sophie Lixenfeld, Jan Nouta, Sofie Keijzer, Federica Linty, Remco Visser, Mads Delbo Larsen, Emily Lara Martin, Inga Künsting, Selina Lehrian, Vera von Kopylow, Carsten Kern, Hanna Bele Lunding, Menno de Winther, Niels van Mourik, Theo Rispens, Tobias Graf, Marleen Adriana Slim, René Peter Minnaar, Marije Kristianne Bomers, Jonne Jochum Sikkens, Alexander P.J. Vlaar, C. Ellen van der Schoot, Jeroen den Dunnen, Manfred Wuhrer, Marc Ehlers, Gestur Vidarsson, Spinello Antinori, Cinzia Bassoli, Giovanna Bestetti, Mario Corbellino, Alice Covizzi, Angelica Lupo, Laura Milazzo, Marco Schiuma, Alessandro Torre, Brent Appelman, Diederik van de Beek, Marije K. Bomers, Justin de Brabander, Matthijs C. Brouwer, David T.P. Buis, Nora Chekrouni, Marit J. van Gils, Menno D. de Jong, Ayesha H.A. Lavell, Niels van Mourik, Sabine E. Olie, Edgar J.G. Peters, Tom D.Y. Reijnders, Michiel Schinkel, Alex R. Schuurman, Jonne J. Sikkens, Marleen A. Slim, Yvo M. Smulders, Alexander P.J. Vlaar, Lonneke A. van Vught, Joost W. Wiersinga
Ebiomedicine, 2023
Mortality among Italians and immigrants with COVID-19 hospitalised in Milan, Italy: data from the Luigi Sacco Hospital registry
Andrea Giacomelli, Anna Lisa Ridolfo, Cecilia Bonazzetti, Letizia Oreni, Federico Conti, Laura Pezzati, Matteo Siano, Cinzia Bassoli, Giacomo Casalini, Marco Schiuma, Alice Covizzi, Matteo Passerini, Marco Piscaglia, Fabio Borgonovo, Claudia Galbiati, Riccardo Colombo, Emanuele Catena, Giuliano Rizzardini, Laura Milazzo, Massimo Galli, Antonio Brucato, Spinello Antinori
BMC Infectious Diseases, 2022
Definition of the Immune Parameters Related to COVID-19 Severity
Sarah Birindelli, Maciej S. Tarkowski, Marcello Gallucci, Marco Schiuma, Alice Covizzi, Przemysław Lewkowicz, Elena Aloisio, Felicia Stefania Falvella, Alberto Dolci, Agostino Riva, Massimo Galli, Mauro Panteghini
Frontiers in Immunology, 2022
Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History
Maciej Tarkowski, Wilco de Jager, Marco Schiuma, Alice Covizzi, Alessia Lai, Arianna Gabrieli, Mario Corbellino, Annalisa Bergna, Carla Della Ventura, Massimo Galli, Agostino Riva, Spinello Antinori
Frontiers in Immunology, 2021
Rapid lateral-flow immunochromatographic tests to assess anti N/S IgG seropositivity after BNT162b2 vaccine: A cross-sectional study: Rapid lateral-flow immunochromatographic tests after BNT162b2 vaccine.
Laura Pezzati, Andrea Giacomelli, Davide Mileto, Federico Conti, Gloria Gagliardi, Alberto Rizzo, Laura Milazzo, Marco Schiuma, Alice Covizzi, Matteo Siano, Cinzia Bassoli, Matteo Passerini, Marco Piscaglia, Alessandro Torre, Letizia Oreni, Giuliano Rizzardini, Massimo Galli, Anna Lisa Ridolfo, Spinello Antinori
Journal of Infection, 2021
The importance of anamnesis in differential diagnosis: A case of sars-cov-2 and dengue virus co-infection
Infezioni in Medicina, 2021
Drug–Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy
Dario Cattaneo, Luca Pasina, Aldo Pietro Maggioni, Andrea Giacomelli, Letizia Oreni, Alice Covizzi, Lucia Bradanini, Marco Schiuma, Spinello Antinori, Annalisa Ridolfo, Cristina Gervasoni
Drugs and Aging, 2020
Invasive pulmonary aspergillosis complicating SARS-CoV-2 pneumonia: A diagnostic challenge
Spinello Antinori, Roberto Rech, Laura Galimberti, Antonio Castelli, Elena Angeli, Tommaso Fossali, Davide Bernasconi, Alice Covizzi, Cecilia Bonazzetti, Alessandro Torre, Luca Carsana, Cristina Tonello, Pietro Zerbi, Manuela Nebuloni
Travel Medicine and Infectious Disease, 2020
30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study
Andrea Giacomelli, Anna Lisa Ridolfo, Laura Milazzo, Letizia Oreni, Dario Bernacchia, Matteo Siano, Cecilia Bonazzetti, Alice Covizzi, Marco Schiuma, Matteo Passerini, Marco Piscaglia, Massimo Coen, Guido Gubertini, Giuliano Rizzardini, Chiara Cogliati, Anna Maria Brambilla, Riccardo Colombo, Antonio Castelli, Roberto Rech, Agostino Riva, Alessandro Torre, Luca Meroni, Stefano Rusconi, Spinello Antinori, Massimo Galli
Pharmacological Research, 2020

Alice Covizzi

RESEARCH, TEACHING, or OTHER INTERESTS

Scopus Publications